Disease block
L20-L30 – Dermatitis und Ekzem
- Chapter XII: Krankheiten der Haut und der Unterhaut
18Decisions
24Patient groups
Added benefit by patient group
- Considerable3
- Non-quantifiable5
- Not proven16
Diseases in this disease block
- L20 Atopisches [endogenes] Ekzem 14 decisions
- L23 Allergische Kontaktdermatitis 1 decision
- L24 Toxische Kontaktdermatitis 1 decision
- L25 Nicht näher bezeichnete Kontaktdermatitis 1 decision
- L28 Lichen simplex chronicus und Prurigo 2 decisions
- L29 Pruritus 2 decisions
- L30 Sonstige Dermatitis 1 decision
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2025-08-07NemluvioNemolizumabNot proven
- 2025-08-07NemluvioNemolizumabNot proven
- 2025-04-03AnzupgoDelgocitinibNot proven: 2 of 2 patient groups
- 2024-10-17CibinqoAbrocitinibNot proven
- 2024-06-06EbglyssLebrikizumabNot proven
- 2024-05-02OlumiantBaricitinibNot proven: 3 of 3 patient groups
- 2023-10-05DupixentDupilumabNon-quantifiable
- 2023-09-21DupixentDupilumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-07-06LivmarliMaralixibatNon-quantifiable
- 2023-05-12AdtralzaTralokinumabNot proven
- 2023-04-06KapruviaDifelikefalinNot proven
- 2022-07-07CibinqoAbrocitinibConsiderable
- 2022-02-17RinvoqUpadacitinibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-01-06AdtralzaTralokinumabNot proven
- 2021-07-01DupixentDupilumabNon-quantifiable
- 2021-05-06OlumiantBaricitinibNot proven
- 2020-02-20DupixentDupilumabNon-quantifiable
- 2018-05-17DupixentDupilumabConsiderable
Data status: 2026-10-29